OncoGenex announces fast track designation granted for custirsen
OncoGenex announced the FDA has granted Fast Track designation to the investigation of custirsen when administered in combination with cabazitaxel/prednisone for treatment of men with metastatic castrate-resistant prostate cancer following prior treatment with a docetaxel-containing regimen. April 23, 2014